Company Stock Prices Before and After Public Announcements Related to Oncology Drugs
Rothenstein, Jeffrey M
Tannock, Ian F
Detsky, Allan S
Journal of the National Cancer Institute 2011 Oct 19; 103(20): 1507-12
Phase III clinical trials and Food and Drug Administration (FDA) regulatory decisions are critical for success of new drugs and can influence a company's market valuation. Knowledge of trial results before they are made public (ie, "inside information") can affect the price of a drug company's stock. We examined the stock prices of companies before and after public announcements regarding experimental anticancer drugs owned by the companies.
Showing items related by title, author, creator and subject.
Effect of Restricting Contact Between Pharmaceutical Company Representatives and Internal Medicine Residents on Posttraining Attitudes and Behavior McCormick, Brendan B.; Tomlinson, George; Brill-Edwards, Patrick; Detsky, Allan S. (2001-10-24)
Is This Patient Dead, Vegetative, or Severely Neurologically Impaired? Assessing Outcome for Comatose Survivors of Cardiac Arrest Booth, Christopher M.; Boone, Robert H.; Tomlinson, George; Detsky, Allan S. (2004-02-18)
Part 4: Conflict of Interest Management Before, During, and After the 2010 International Consensus Conference on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations Billi, John E; Shuster, Michael; Bossaert, Leo; de Caen, Allan R; Deakin, Charles D; Eigel, Brian; Hazinski, Mary Fran; Hickey, Robert W; Jacobs, Ian; Kleinman, Monica E; Koster, Rudolph W; Mancini, Mary E; Montgomery, William H; Morley, Peter T; Morrison, Laurie J; Munoz, Henrietta; Nadkarni, Vinay M; Nolan, Jerry P; O'Connor, Robert E; Perlman, Jeffrey M; Richmond, Sam; Sayre, Michael R; Soar, Jasmeet; Wyllie, Jonathan; Zideman, David (International Liaison Committee on Resuscitation; American Heart Association, 2010-10-19)